SynthesisFrontiers in endocrinology2026
Risk association and diagnostic value of body roundness index for cardiovascular-kidney-metabolic-related outcomes: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The accumulation of visceral fat is a pivotal factor in the development and progression of Cardiovascular-Kidney-Metabolic (CKM) Syndrome. The early identification of high-risk individuals is crucial for delaying disease progression. The body roundness index (BRI) is a novel measures for assessing visceral fat, but its association with CKM-related outcomes lacks comprehensive evidence. Methods: A comprehensive literature search was conducted to identify observational studies that examined the association between BRI and CKM-related outcomes. The search was performed in PubMed, Web of Science, and Embase, and updated to July 7, 2025. Effect sizes were pooled using a random-effects model, with heterogeneity and publication bias evaluated. Additionally, a diagnostic meta-analysis was performed to assess the discriminatory ability of BRI for specific metabolic risk factors. Results: A total of 93 studies (involving 13 countries) were included. BRI was significantly associated with the risk of multiple CKM-related outcomes, but its strength varied by outcome and gender subgroup. For metabolic syndrome, BRI exhibited consistent risk associations in the overall population and gender subgroups, with good discriminatory ability in the diagnostic meta-analysis. However, its predictive ability for chronic kidney disease, cardiovascular disease, and mortality was relatively constrained. Conclusion: Within the CKM framework, a significant association between BRI and the risk of multiple CKM-related outcomes has been identified, with favorable risk assessment and discriminatory performance of BRI observed, especially for metabolic abnormalities. As a complementary tool to conventional anthropometric indices, BRI can provide incremental information to optimize the identification and risk stratification of CKM-related risks. Further definition of the long-term predictive value and clinical utility of BRI across diverse global populations is warranted through high-quality prospective cohort studies. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420251110973.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.